Will Vivus’s Stock Price Continue to Shed Weight?

| + More Articles
  • Like on Facebook
  • Share on Google+
  • Share on LinkedIn

E = Equity to Debt Ratio Is Strong

The debt-to-equity ratio for Vivus is excellent. The same can be said for the balance sheet. The three companies listed below in this space all have strong numbers in these areas. The other two companies listed include Arena Pharmaceuticals (NASDAQ:ARNA) and Orexigon Therapeutics (NASDAQ:OREX).  

Debt-To-Equity

Cash

Long-Term Debt

VVUS

0.00

$274.48 Million

$0

ARNA

.62

$165.77 Million

$73.24 Million

OREX

0.00

$108.28 Million

$0

 

T = Technicals on the Stock Chart Are Mixed

Vivus has had a nice run over the past three years, but it has underperformed Arena Pharmaceuticals by a wide margin.

1 Month

Year-To-Date

1 Year

3 Year

VVUS

4.58%

21.90%

14.17%

39.17%

ARNA

4.13%

385.60%

314.60%

164%

OREX

22.43%

232.30%

214.70%

-25.28%

 

At 11.77, Vivus is currently trading below all its averages.

50-Day SMA

15.12

100-Day SMA

18.51

200-Day SMA

21.20

 

E = Earnings and Revenue Are Not a Factor at the Moment

Annual revenue has been wildly sporadic, but this is normal for the majority of the industry. Earnings have been on a steady decline.

2007

2008

2009

2010

2011

Revenue ($)in millions

54.7

83.72

31.40

N/A

N/A

Diluted EPS ($)

-.04

-.13

-.20

-.24

-.40

 

There isn’t enough information to provide an analysis on revenue, but earnings have disappointed on a Q3 YoY basis.

9/2011

12/2011

3/2012

6/2012

9/2012

Revenue ($)in millions

N/A

N/A

N/A

N/A

.41

Diluted EPS ($)

-.10

-.13

-.20

-.24

-.40

 

More Articles About:

To contact the reporter on this story: staff.writers@wallstcheatsheet.com To contact the editor responsible for this story: editors@wallstcheatsheet.com

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business